Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -47.12% | -79.54% | +39.72% | +15.74% | -77.37% |
| Gross Profit Growth | -45.81% | -430.41% | -283.92% | +0.00% | -77.37% |
| EBITDA Growth | -634.22% | -141.23% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -142.99% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -140.80% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -140.21% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -140.63% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.68% | +1.96% | +3.46% | +3.83% | +3.98% |
| Weighted Average Shares Diluted Growth | +2.68% | +1.75% | +3.46% | +3.83% | +3.98% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -19.81% | +0.00% | -167.40% | +0.00% | +36.50% |
| Free Cash Flow Growth | -19.81% | +0.00% | -167.40% | +0.00% | +36.50% |
| Receivables Growth | +1682.60% | +3.51% | -55.22% | -51.83% | -95.38% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +26.20% | -39.39% | -53.66% | -58.55% | -59.92% |
| Book Value per Share Growth | +18.79% | -57.68% | -66.04% | -60.73% | -61.10% |
| Debt Growth | -20.73% | -22.48% | -24.49% | -26.79% | -27.50% |
| R&D Expense Growth | +63.87% | +74.16% | -21.50% | -55.02% | -68.00% |
| SG&A Expenses Growth | -8.93% | +9.68% | +15.33% | +6.24% | -19.70% |